Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)

Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference

Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

Proceeds Will Fund the Development of Haduvio for Severe Chronic Pruritus in Prurigo Nodularis and Chronic Cough in Idiopathic Pulmonary Fibrosis